| Literature DB >> 35479564 |
Ting Li1, Da-Bo Pan1,2, Qian-Qian Pang1, Mi Zhou1, Xiao-Jun Yao3, Xin-Sheng Yao1, Hai-Bo Li4, Yang Yu1.
Abstract
Eight previously undescribed diarylheptanoids (1-8), together with fifteen known analogues (9-23), were isolated from the rhizomes of Zingiber officinale. Their structures were unambiguously determined by comprehensive spectroscopic analyses and electronic circular dichroism (ECD) calculations. It is worth mentioning that 1-3 are the first reported structures of diaryl ether heptanoids in Z. officinale, whereas 15-17 were isolated from Zingiber for the first time. Furthermore, a gene enrichment analysis of the interacting targets indicated that diarylheptanoids were mainly associated with the anti-tumor activity by affecting DNA damage signaling pathway. The results showed that 6, 16-19 had remarkable inhibitory effects against five tumor cell lines (A549, HepG2, HeLa, MDA-MB-231, and HCT116) with IC50 values ranging from 6.69-33.46 μM, and showed down-regulating the expression of ATR (ataxia telangiectasia mutated and RAD3-related) and CHK1 (checkpoint kinase 1) levels in HCT116 and A549 cell lines. Our studies not only enrich the structural diversity of diarylheptanoids in nature, but also discover several natural compounds for anti-tumor agents. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35479564 PMCID: PMC9040573 DOI: 10.1039/d1ra03592d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
1H (600 MHz) and 13C (150 MHz) NMR data of compounds 1–3
| Pos. | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 29.2 | 2.85, ddd (16.4, 8.7, 2.4) | 33.6 | 3.01 | 32.9 | 2.96, ddd (12.9, 5.8, 2.9) |
| 2.95 | 3.04, dt (12.9, 5.8) | |||||
| 2 | 42.0 | 2.49, ddd (15.0, 8.7, 2.4) | 43.9 | 2.64 | 44.6 | 2.51 |
| 2.79, dt (12.2, 5.8) | ||||||
| 3 | 201.1 | 200.8 | 215.6 | |||
| 4 | 131.8 | 5.86, d (15.2) | 131.4 | 5.73, dt (15.3, 1.5) | 52.4 | 1.89, d (18.3) |
| 2.22, dd (18.3, 10.5) | ||||||
| 5 | 147.9 | 6.58, ddd (15.2, 8.6, 7.5) | 148.2 | 6.56, dt (15.3, 7.0) | 66.1 | 3.34, br t (8.4) |
| 6 | 35.1 | 2.44 | 32.8 | 2.34 | 34.8 | 1.65 |
| 2.59, dq (12.6, 6.3) | 1.33 | |||||
| 7 | 34.6 | 2.95 | 32.0 | 2.70 | 29.0 | 2.49 |
| 2.72, ddd (16.8, 11.4, 2.1) | ||||||
| 1′ | 132.6 | 132.7 | 131.4 | |||
| 2′ | 106.5 | 6.38, d (1.8) | 105.7 | 6.28, d (1.7) | 105.9 | 6.34, br s |
| 3′ | 149.6 | 147.3 | 147.9 | |||
| 4′ | 134.1 | 132.9 | 133.1 | |||
| 5′ | 149.9 | 147.9 | 147.6 | |||
| 6′ | 106.3 | 4.99, d (1.8) | 106.8 | 5.52, d (1.7) | 107.4 | 5.33, br s |
| 1′′ | 140.8 | 138.5 | 138.0 | |||
| 2′′ | 115.8 | 6.80, d (1.8) | 114.9 | 6.77, d (1.8) | 116.2 | 6.59, d (1.8) |
| 3′′ | 154.0 | 152.7 | 151.9 | |||
| 4′′ | 144.1 | 143.5 | 145.2 | |||
| 5′′ | 125.1 | 6.92, d (8.0) | 124.6 | 7.01, d (8.0) | 124.7 | 7.21, d (8.0) |
| 6′′ | 122.5 | 6.73, dd (8.0, 1.8) | 121.8 | 6.83, dd (8.0, 1.8) | 120.2 | 6.93, dd (8.0, 1.8) |
| 3′-OCH3 | 56.7 | 3.82, s | 56.4 | 3.87, s | 56.4 | 3.87, s |
| 3′′-OCH3 | 56.6 | 3.68, s | 56.5 | 3.72, s | 56.3 | 3.59, s |
Measured in CD3OD.
Measured in CDCl3.
Fig. 2Key 1H–1H COSY and HMBC correlations of compound 1.
Fig. 1Structures of compounds 1–23.
1H and 13C NMR data of compounds 4–6
| Pos. | 4 | 5 | 6 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 30.3 | 2.74 | 29.9 | 2.82, t (7.4) | 30.8 | 2.86, t (7.0) |
| 2 | 46.4 | 2.74 | 46.0 | 2.73 | 41.7 | 2.81, t (7.0) |
| 3 | 211.7 | 208.9 | 200.1 | |||
| 4 | 48.7 | 2.67, dd (15.8, 7.1) | 47.6 | 2.45, dd (15.9, 5.3) | 131.1 | 6.07, d (15.8) |
| 2.55, dd (15.8, 7.1) | 2.71, dd (15.9, 7.1) | |||||
| 5 | 76.3 | 3.72, dt (12.1, 6.1) | 76.8 | 3.69 | 147.0 | 6.77, dd (15.8, 6.9) |
| 6 | 37.5 | 1.71 | 36.2 | 1.76 | 34.3 | 2.47 |
| 7 | 32.1 | 2.54 | 31.2 | 2.55, ddd (15.6, 9.8, 6.6) | 33.8 | 2.64, t (7.1) |
| 2.63, ddd (15.6, 9.8, 5.8) | ||||||
| 8 | 65.6 | 3.42, qd (7.1, 2.0) | 57.2 | 3.31, s | — | — |
| 9 | 15.8 | 1.10, t (7.1) | — | — | — | — |
| 1′ | 134.0 | 132.3 | 137.3 | |||
| 2′ | 113.1 | 6.75, d (1.5) | 105.1 | 6.39, s | 105.6 | 6.39, s |
| 3′ | 148.9 | 147.1 | 153.3 | |||
| 4′ | 145.6 | 133.1 | 136.3 | |||
| 5′ | 116.2 | 6.68, d (8.0) | 147.1 | 153.3 | ||
| 6′ | 121.8 | 6.58, dd (8.0, 1.5) | 105.1 | 6.39, s | 105.6 | 6.39, s |
| 1′′ | 134.8 | 133.9 | 133.6 | |||
| 2′′ | 113.2 | 6.73, d (1.6) | 111.0 | 6.67, br s | 115.5 | 6.63, br s |
| 3′′ | 148.9 | 146.5 | 143.9 | |||
| 4′′ | 145.8 | 143.9 | 142.1 | |||
| 5′′ | 116.2 | 6.70, d (8.0) | 114.4 | 6.82, d (7.9) | 115.5 | 6.75, d (6.9) |
| 6′′ | 121.8 | 6.61, dd (8.0, 1.6) | 121.0 | 6.65, br d (7.9) | 120.7 | 6.55, br d (6.9) |
| 3′-OCH3 | 56.4 | 3.80, s | 56.4 | 3.86, s | 56.3 | 3.83, s |
| 4′-OCH3 | — | — | — | — | 61.1 | 3.82, s |
| 5′-OCH3 | — | — | 56.4 | 3.86, s | 56.3 | 3.83, s |
| 3′′-OCH3 | 56.4 | 3.82, s | 56.0 | 3.87, s | — | — |
Measured in CD3OD.
Measured in CDCl3.
400 MHz for 1H, 100 MHz for 13C.
600 MHz for 1H, 150 MHz for 13C.
1H (600 MHz) and 13C (150 MHz) NMR data of compounds 7–8 in CDCl3
| Pos. | 7 | 8 | ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 31.6 | 2.58 | 32.1 | 2.59 |
| 2.51, td (7.0, 2.7) | 2.51, td (7.2, 2.0) | |||
| 2 | 36.2 | 1.84 | 36.0 | 1.86 |
| 1.76 | 1.76 | |||
| 3 | 73.8 | 4.90 | 73.5 | 4.92 |
| 4 | 34.0 | 1.56 | 33.8 | 1.56 |
| 5 | 24.7 | 1.30 | 24.7 | 1.29 |
| 6 | 31.1 | 1.51 | 30.9 | 1.49 |
| 7 | 35.0 | 2.46, td (7.5, 1.7) | 34.9 | 2.4, t (7.6) |
| 1′ | 133.7 | 132.9 | ||
| 2′ | 111.2 | 6.66, br s | 105.3 | 6.40, s |
| 3′ | 146.5 | 147.0 | ||
| 4′ | 143.8 | 132.9 | ||
| 5′ | 114.5 | 6.83, d (7.9) | 147.0 | |
| 6′ | 120.9 | 6.65 | 105.3 | 6.40, s |
| 1′′ | 135.4 | 135.4 | ||
| 2′′ | 115.5 | 6.64, br s | 115.4 | 6.59, d (1.5) |
| 3′′ | 143.5 | 143.4 | ||
| 4′′ | 141.8 | 141.8 | ||
| 5′′ | 115.2 | 6.76, d (7.6) | 115.2 | 6.75, d (8.0) |
| 6′′ | 121.0 | 6.56, br d (7.6) | 120.9 | 6.56, dd (8.0, 1.5) |
| 3-OAc | 171.4 | 171.3 | ||
| 21.4 | 2.03, s | 21.4 | 2.04, s | |
| 3′-OCH3 | 56.1 | 3.87, s | 56.5 | 3.87, s |
| 5′-OCH3 | — | — | 56.5 | 3.87, s |
Fig. 3Potential anti-tumour target-compound network (blue stands for the compounds, purple represents the cancer related targets, and red means key targets).
Fig. 4GO enrichment analysis of diarylheptanoids in the treatment of cancer.
Cytotoxicity activities of compounds 6, and 16–19
| Compound | Cytotoxic activity IC50/μmol L−1 | ||||
|---|---|---|---|---|---|
| A549 | HepG2 | HeLa | MDA-MB-231 | HCT116 | |
| 6 | 17.49 ± 0.09 | 33.46 ± 0.50 | 30.46 ± 1.20 | 17.83 ± 0.11 | 14.70 ± 0.63 |
| 16 | 13.74 ± 0.48 | 19.67 ± 0.09 | 11.30 ± 0.36 | 10.78 ± 0.12 | 13.88 ± 0.18 |
| 17 | 11.49 ± 0.11 | 15.98 ± 0.14 | 10.41 ± 0.43 | 9.18 ± 0.18 | 10.61 ± 0.21 |
| 18 | 8.63 ± 0.42 | 13.06 ± 0.13 | 11.56 ± 0.21 | 10.51 ± 0.14 | 6.69 ± 0.09 |
| 19 | 17.27 ± 0.21 | 20.93 ± 0.41 | 12.20 ± 0.16 | 13.60 ± 0.05 | 11.64 ± 0.18 |
| Curcumin | 21.86 ± 0.25 | 27.37 ± 0.30 | 19.71 ± 0.22 | 19.03 ± 0.11 | 14.88 ± 0.14 |
Paclitaxel was used as a control.
Fig. 5Effects of compounds 6, 17, and 18 on the protein expressions of ATM, ATR, P53, and CHK1 in HCT116 cell line. HCT116 cells were pre-treated with different concentrations of 6, 17, and 18 for 24 h. The cells were lysed with RIPA buffer and the protein levels for total ATM, ATR, P53, and CHK1 were measured by using immunoblot analysis. β-Actin was used as a loading control. CPT was used as a positive control. And all of the experiments have been repeated three times independently. Data presented as mean ± SD, n = 3. *p < 0.05, **p < 0.01, and ***p < 0.001 as compared with the DMSO group.